Skip to main
KIDS

OrthoPediatrics (KIDS) Stock Forecast & Price Target

OrthoPediatrics (KIDS) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 56%
Buy 33%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

OrthoPediatrics Corp is demonstrating a robust performance, with Trauma & Deformity sales increasing by 17.3% to $44.1 million, surpassing expectations, while EBITDA margins improved significantly by 280 basis points year-over-year, highlighting effective cost management and operational efficiency. The company's consistent growth in core dynamics, particularly with over 20% growth in OPSB sales, positions it favorably for future expansion. Furthermore, the introduction of new products is anticipated to enhance margins and drive further revenue growth, presenting a strong financial outlook for the company.

Bears say

OrthoPediatrics Corp is facing several fundamental challenges that contribute to a negative outlook on its stock, including a slowdown in revenue growth, which decelerated to 12.2% in the third quarter of 2025 from 15.7% in the previous quarter. The company has also observed a decrease in the deployment of surgical sets, down to $16.0 million from $17.2 million, indicating potential issues in sales rep retention and the efficacy of new product launches. Additionally, OrthoPediatrics has revised downward its fiscal year 2025 revenue guidance amid these challenges, signaling further erosion in its financial performance.

OrthoPediatrics (KIDS) has been analyzed by 9 analysts, with a consensus rating of Buy. 56% of analysts recommend a Strong Buy, 33% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OrthoPediatrics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OrthoPediatrics (KIDS) Forecast

Analysts have given OrthoPediatrics (KIDS) a Buy based on their latest research and market trends.

According to 9 analysts, OrthoPediatrics (KIDS) has a Buy consensus rating as of Jan 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OrthoPediatrics (KIDS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.